inpremzia
baxter holding b.v. - insulin human (rdna) - sykursýki - lyf notuð við sykursýki - inpremzia is indicated for the treatment of diabetes mellitus.
bimervax
hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - bóluefni - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.
albuman innrennslislyf, lausn 200 g/l
prothya biosolutions netherlands b.v. - human serum albumin - innrennslislyf, lausn - 200 g/l
albuman innrennslislyf, lausn 40 g/l
prothya biosolutions netherlands b.v. - human albumin - innrennslislyf, lausn - 40 g/l
albumin baxalta (albumin baxter) innrennslislyf, lausn 200 g/l
baxalta innovations gmbh - human albumin - innrennslislyf, lausn - 200 g/l
albumin baxalta (albumin baxter) innrennslislyf, lausn 50 g/l
baxalta innovations gmbh - human albumin - innrennslislyf, lausn - 50 g/l
fibryga stungulyfs-/innrennslisstofn og leysir, lausn 1 g
octapharma ab - human fibrinogen - stungulyfs-/innrennslisstofn og leysir, lausn - 1 g
flexbumin innrennslislyf, lausn 200 g/l
baxalta innovations gmbh - human serum albumin - innrennslislyf, lausn - 200 g/l
riastap stungulyfs-/innrennslisstofn, lausn 1 g
csl behring gmbh* - human fibrinogen - stungulyfs-/innrennslisstofn, lausn - 1 g
tisseel lausnir fyrir vefjalím
baxter medical ab - human fibrinogen; human factor xiii; bovine aprotinin; human thrombin; calcii chloridum; thrombin; protein - lausnir fyrir vefjalím